UT Southwestern Scientists Develop Targeted Gene Therapy for Alpha-1 Antitrypsin Deficiency Using Designer Lipid Nanoparticles
核心洞察
Researchers at UT Southwestern Medical Center (搜索) have developed selective organ targeting lipid nanoparticles (搜索) that successfully delivered gene therapy to both lung and liver cells in mice with alpha-1 antitrypsin deficiency (搜索).
The innovative approach corrected approximately 40% of liver cells and 10% of lung cells, leading to 80% restoration of normal liver function and 90% restoration of lung function.
The breakthrough addresses a major challenge in gene therapy by enabling targeted delivery to specific organs beyond the liver, where nanoparticles typically accumulate.
Researchers at UT Southwestern Medical Center (搜索) have achieved a significant breakthrough in gene therapy by developing lipid nanoparticles (搜索) capable of targeting both lung and liver cells to treat alpha-1 antitrypsin deficiency (搜索), a rare genetic disorder affecting 80,000 to 100,000 Americans. The study, published in Nature Biotechnology, demonstrates successful DNA repair in animal models and represents a major advance in overcoming the challenge of directing gene therapies to specific organs.
Revolutionary Targeting Technology
The research team, led by Professor Daniel Siegwart from UTSW's biomedical engineering department, solved a fundamental problem that has plagued the field for over a decade. Traditional lipid nanoparticles (搜索) naturally accumulate in the liver, limiting their therapeutic potential for diseases affecting other organs.
"When I joined [UTSW] in 2012, I wrote the top five challenges in my field on a whiteboard," Siegwart explained. "One of those problems was that all nanoparticles accumulate in the liver. It's great for liver disease, but it's going to hinder therapies for everything else."
The breakthrough came through the addition of a fifth lipid component called DORI (搜索) to the standard four-lipid nanoparticle formulation. This modification enabled the particles to bypass the liver entirely and target lung cells specifically, while maintaining the ability to also deliver therapy to liver cells when needed.
Impressive Therapeutic Results
In genetically engineered mice with alpha-1 antitrypsin deficiency (搜索), the selective organ targeting lipid nanoparticles (搜索) delivered base editors that corrected the mutated SERPINA1 (搜索) gene. The results exceeded expectations, with approximately 40% of liver cells and 10% of lung cells successfully corrected.
"We found that level of correction led to 80% restoration of the normal liver and about 90% restoration of the lungs," Siegwart reported. The therapy also reduced levels of abnormal protein associated with the genetic condition by over 80%.
The gene-editing effects demonstrated remarkable durability, persisting for 32 weeks in the study animals. Dr. Terence Flotte, a pediatric pulmonologist and dean of the University of Massachusetts T.H. Chan Medical School who was not involved in the research, praised the achievement: "[The researchers] are getting results that haven't been gotten before. It looks pretty darn convincing to me."
Addressing an Unmet Medical Need
Alpha-1 antitrypsin deficiency (搜索) results from mutations in the SERPINA1 (搜索) gene, which normally produces a protective protein in the liver that travels to the lungs to guard against neutrophil elastase (搜索), an enzyme released during inflammation. When this protein is missing or misshapen due to genetic mutations, it clumps in the liver instead of reaching the lungs, allowing neutrophil elastase to damage healthy lung tissue.
Current treatments like augmentation therapy, which uses plasma from healthy donors to raise protein levels, can ease symptoms but provide no cure. The dual-organ targeting capability of the new lipid nanoparticles (搜索) addresses both the liver dysfunction and lung damage associated with the condition.
Broader Therapeutic Applications
The technology's potential extends beyond alpha-1 antitrypsin deficiency (搜索). Siegwart and his team are exploring applications for other genetic diseases, including cystic fibrosis (搜索) and primary ciliary dyskinesia (搜索), a rare disorder affecting the hair-like structures lining airways.
California-based ReCode Therapeutics (搜索), which Siegwart co-founded, is already advancing these lipid nanoparticles (搜索) as delivery vehicles for gene therapies targeting both conditions. In March, the company received Orphan Drug Designation from the FDA for an investigational cystic fibrosis (搜索) gene therapy.
Clinical Translation Pathway
The research comes as the field of gene therapy for alpha-1 antitrypsin deficiency (搜索) gains momentum. Boston-based Beam Therapeutics announced initial data in March from an early-stage clinical trial of BEAM-302, a gene therapy targeting the SERPINA1 (搜索) mutation in the liver.
However, the UT Southwestern approach offers potential advantages by addressing the disease in both affected organs simultaneously. As Flotte noted, there is "an accumulating body of evidence that some element of the lung disease occurs because the mutant alpha-1 antitrypsin made right there in the lungs is harmful."
Future research will focus on validating the approach in additional animal models, including ferrets with alpha-1 antitrypsin deficiency (搜索), which allow for testing protocols similar to those used in humans. The team also plans to investigate the long-term durability of the gene-editing effects and optimize the therapy for potential clinical translation.